Nyxoah S.A (NYXH): Market Capitalization-to-Revenue Ratio

Symbol and logo of brand Nyxoah, S.A. (NYXH)

P/S levels on the chart help assess the business valuation relative to revenue, with 2.80 representing the most recent level. Nyxoah S.A. (NYXH) operates within a stable Western jurisdiction free from political threats. Growth is expected following FDA approval of the Genio system and the expansion of insurance coverage. However, slow adoption of neurostimulation and pressure from traditional therapy methods create certain commercial risks.

Price-to-Revenue Ratio: Nyxoah (NYXH) for 07/04/2022 - 11/17/2026
Mass-produced product of nyxoah.com

The P/S ratio determines the market value of a business relative to its annual sales volume, allowing for an assessment of the premium paid for every dollar of revenue. By analyzing the P/S trajectory, an investor compares the market capitalization of Nyxoah S.A. (NYXH) with the sales efficiency of its apnea therapy implants, while accounting for costs associated with environmental production upgrades and the disposal of specific medical waste.

Competitors of Nyxoah S.A.

Market Cap to Sales Volume ISRG|Danaher Corporation - Market Cap to Revenue|P/S Multiple Becton Dickinson & Company BDX|STE - Price-to-Revenue Ratio|West Pharmaceutical Services (WST) - Market Cap to Revenue|BAX: P/S Multiple|Market Cap to Revenue Masimo|STVN (stevanatogroup.com) - P/S Multiple|Market Cap to Revenue Ratio TFX (Teleflex Incorporated)|Price-to-Revenue Ratio Merit Medical (MMSI)|Envista - Market Cap to Revenue Ratio|ICU Medical, Inc. - Market Cap to Revenue|Market Cap to Sales Volume XRAY (Dentsply Sirona Inc)|LMAT - Price-to-Revenue Ratio|Price-to-Revenue Coefficient AtriCure Corp ATRC|staar.com (STAA) - Price-to-Revenue Ratio|Market Cap to Revenue ChromaDex Corporation|ZIMV (ZimVie Inc) - P/S Multiple|Market Cap to Revenue Ratio ANGO (AngioDynamics)|Price-to-Revenue Ratio Cerus Corp (CERS)|TKNO: Price-to-Sales Ratio|Price-to-Revenue Ratio Monogram Technologies Inc. MGRM|Market Capitalization-to-Revenue Ratio STSS|INFU - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio UTMD (Utah Medical Products Inc.)|KORU Medical Systems Inc. (KRMD) - Price-to-Revenue Ratio|MBOT (Microbot Medical, Inc) - Price-to-Revenue Ratio|Market Cap to Revenue PDEX|ZTEK: Market Capitalization-to-Revenue Ratio|P/S Multiple ELUT|Milestone Scientific Inc. - Market Cap to Revenue Ratio|Price-to-Revenue Ratio NEXGEL, Inc. NXGL|Retractable Tech - Price-to-Revenue Ratio|harvardbioscience.com - P/S Multiple|FEMY (Femasys Inc.) - Market Cap to Revenue Ratio|MHUA: P/S Multiple|Predictive Oncology Corp - Market Capitalization-to-Revenue Ratio|CJMB (Callan JMB) - P/S Multiple|Price to Sales Atrion Corporation Inc. ATRI|P/S Multiple NURO